Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 19, 2025
Emerging Company Profile
Trio: Introducing two new types of dual-targeting antibodies for cancer
San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Nov 16, 2024
Data Byte
EMA’s CHMP finds path to Leqembi nod, backs three other new drugs
Eleven label expansions also among committee’s November recommendations
BioCentury | Oct 15, 2024
Emerging Company Profile
Commit: Activating the complement pathway to deeply deplete target cells
Launched in May, Danish company’s tech engages C1q to trigger complement-induced killing of cancer or autoimmune cells
BioCentury | Oct 1, 2024
Product Development
BCMA CAR Ts diverge in early lines, as Carvykti dominates market
In BioCentury’s latest Clinical Report, AbbVie hits in Parkinson’s, plus data from Shattuck, Merck and Celldex
BioCentury | Aug 30, 2024
Data Byte
Nine PDUFA dates on FDA’s agenda in September
Decision on Zevra’s arimoclomol follows positive AdCom vote
BioCentury | Aug 14, 2024
Finance
Seeding the next wave of myeloma drug development
How the Myeloma Investment Fund approaches venture philanthropy and views the future of the myeloma treatment landscape
Items per page:
1 - 10 of 296